Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.51 |
| ▸ | CA2 | P00918 | 10/20 | 0.51 |
| ▸ | CA9 | Q16790 | 8/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | PPM1B | O75688 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13868767 | 1.00 | CA1 (0.51) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL13201071 | 1.00 | CA1 (0.51) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL1897870 | 0.85 | CA1 (0.49) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL31715807 | 0.85 | CA1 (0.49) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL12889180 | 0.83 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL15927849 | 0.83 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL11946139 | 0.83 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL13868765 | 0.83 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL6871204 | 0.83 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL17407788 | 0.83 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073678-A2 | PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE | OMEGA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-115003673-B | Dihydropyrimidine compound, preparation method and application thereof | 上海维申医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115003673-A | Dihydropyrimidine compound, and preparation method and application thereof | 上海维申医药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022121844-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022121844-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114621219-A | Dihydropyrimidine compound, and preparation method and application thereof | 上海维申医药有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-2498605-B1 | DIURETICS | MERCK SHARP & DOHME (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8354394-B2 | Diuretics | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2498605-A1 | DIURETICS | Merck Sharp & Dohme Corp. (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20120208838-A1 | DIURETICS | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011053519-A1 | DIURETICS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-5416231-A | Prostaglandin I2 derivatives | ASAHI GLASS COMPANY, LTD. (JP) | 1995-05-16 | — | — | US | disclosed |
| EP-0553352-B1 | NOVEL PROSTAGLANDIN I2 DERIVATIVES | ASAHI GLASS CO LTD (JP) | 1995-03-15 | — | — | EP | disclosed |
| EP-0553352-A1 | NOVEL PROSTAGLANDIN I2 DERIVATIVES | ASAHI GLASS COMPANY LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992004339-A1 | NOVEL PROSTAGLANDIN I2 DERIVATIVES | ASAHI GLASS COMPANY LTD. (JP) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208838-A1 | DIURETICS | REN, AGTR1, AGTR2 | CA1 1651/4885CA2 131/4885CA9 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.